跳至主要内容
临床试验/EUCTR2004-002312-29-ES
EUCTR2004-002312-29-ES进行中(未招募)不适用

The Effects of Nitric Oxide for Inhalation on the development of chronic lung disease in pre-term infants. - INOT-27

INO Therapeutics0 个研究点目标入组 600 人开始时间: 2006年1月23日最近更新:
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
600

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • -Inborn preterm infants 24+0 weeks–28+6 weeks gestational age (defined by first ultrasound at 16-18 weeks or if not available based on the last menstrual period) who requires the use of surfactant within 12 hours of birth, (either prophylactically or for signs of developing respiratory distress), or who requires the use of CPAP (FiO2 =0.30 and mean airway pressure =4cm H2O) within 12 hours of birth in order to maintain an SpO2 =85%.
  • -Informed consent of the parent or legal guardian.
  • CPAP- Continuous Positive Airway Pressure
  • SpO2- Oxygen Saturation by pulse oximeter
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - Outborn infants.
  • - Infants = 29 weeks gestational age.
  • - Infants with birth weight <500 grams.
  • - Infants requiring FiO2 >0.5 to maintain SpO2 >85%, on a sufficient mean airway pressure (e.g. > 8 cm H2O on CMV ) in order to achieve adequate chest inflation (8-9 ribs on Chest X-ray) two hours after the proper administration of exogenous surfactant.
  • - Any suspected congenital heart disease other than patent ductus arteriosus or atrial septal defect.
  • - Any infant with suspected lung hypoplasia associated with congenital diaphragmatic hernia
  • - Any infant with severe bleeding or coagulation abnormalities at high-risk of diathesis, e.g., platelet <50,000/mm3, fibrinogen <0.5 g/L, other clotting factors <10%.
  • - Any infant in whom a decision has been made not to provide full treatment, e.g., chromosomal abnormalities, severe multiple abnormalities, severe birth asphyxia, etc.
  • - Use of another investigational drug or device before or during the active study period
  • CMV- Controlled Mechanical Ventillation

研究者

发起方
INO Therapeutics

相似试验